Labs and physicals completed every two months. Medtronic Quality of Life Cancer patients entering this study are randomized to one of two groups. The first group will continue to receive therapy as would be expected. Patients in the second group receive a SynchroMed intrathecal pump. Patients randomized to the first group are eligible for a pump after four weeks.
Study lasts for six months.
Patients must have a life expectancy of at least three months and on a minimum narcotic dosage equal to 200mg oral morphine. Smaller doses are allowed if side effects are too great. Investigator decides drug used in pump. Patients must be at a point in their care in which the next step is intrathecal management. Current narcotic regimen is not required.